Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia;Intravitreal bevacizumab bei choroidaler neovaskularisation infolge pathologischer myopie

Ophthalmologe

Volumn 106, Issue 6, 2009, Pages 527-530

  Dithmar, S ^a,b   Schaal, K B ^a   Hoh A E ^a   Schmidt, S ^a   Schutt F ^a  

^a Universitätsaugenklinik   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Anti VEGF therapy; Bevacizumab; Choroidal neovascularization (CNV); Myopia; VEGF

Indexed keywords

EID: 67949117084     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-008-1806-z     Document Type: Article

References (18)

1. Chan WM, Lai TY, Liu DT et al. (2007) Intravital bevacizumab (avastin) for myopic choroidal neovascularization. Ophthalmology 114:2190-2196
2. Degenring RF, Jonas JB (2005) Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 83:621
3. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. BrJ Ophthalmol 90:1344-1349
4. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhauszet al (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707-712
5. Laud K, Spaide RF, Freund KB et al (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963
6. Mandai S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (avastin) as primary treatment for myopie choroidal neovascularization. Eur J Ophthalmol 17:620-626
7. Nguyen QD, Shah S, Tatlipinar S et al (2005) Bevacizumab supresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89:1368-1370
8. Potter MJ, Szabo SM, HoT (2005) Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year old girl. Graefe's Arch Clin Exp Ophthalmol 21:1-3
9. Rosenfeld PJ (2006) Intravitreal avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 91:128-130
10. Sagaguchi H, Ikuno Y, Gomi F et al (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165
11. Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7:307-316
12. Schaal KB, Höh AE, Scheuerle A et al (2007) Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäß verschlüsse. Ophthalmologe 104:285-289
13. Tewari A. Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093-1094
14. Verteporfin in PhotodynamicTherapy (VIP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial -VIP report No 1. Ophthalmology 108:841-852
15. Verteporfin in Photodynamic Therapy (VIP) Study Group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. VIP report No 3. Ophthalmology 110:667-673
16. Xu L, Wang Y, Li Y et al (2006) Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 113:1-3
17. Yamamoto I, Rogers AH, Reichel E et al (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157-160
18. Yoshida T, Ohno-Matsui K, Ohtake Y et al (2002) Long-term visual prognosis of choroidal neovascularization in high-myopia: a comparison between age groups. Ophthalmology 109:712-719